Rua Bioscience (RUA) H2 2024 earnings summary

Executive summary

• Q1 FY25 sales exceeded double the total sales of FY24, reaching approximately $240,000.

• Strategic focus on genetics and distribution has established sales pipelines in Germany, Australia, and soon the UK.

• Directors remain confident in the business trajectory despite going concern uncertainties.

Financial highlights

• Q1 FY25 sales already over double FY24 total sales, driven by export-led growth.

• Received $150,000 in equity from existing shareholders.

Outlook and guidance

• Sales momentum expected to continue for the remainder of FY25.

• Targeting positive cash flow by the end of 2025.

• UK market entry anticipated by year-end, expanding presence to four key markets.